Granissetrom Hameln (Granisetron Hydrochloride)

Granissetrom Hameln is indicated for the prevention of nausea and vomiting in specific clinical settings. It is commonly administered intravenously before exposure to emetogenic stimuli.

• Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients.
• Prevention of postoperative nausea and vomiting (PONV) following surgical procedures.
• Adjunct therapy for radiotherapy‑related nausea when combined with other antiemetics.
• Use in patients receiving highly emetogenic chemotherapy regimens.
• Optional pre‑emptive dosing for patients with a history of severe nausea.

The safety profile of Granissetrom Hameln includes both frequent, mild reactions and less common, potentially serious events.

Common

• Headache – mild to moderate intensity, often transient.
• Constipation – reduced bowel movements that may improve with supportive care.
• Fatigue – general feeling of tiredness without fever.
• Transient dizziness – brief episodes of light‑headedness, usually resolving quickly.

Serious

• Severe allergic reaction (anaphylaxis) – rapid onset of rash, swelling, breathing difficulty.
• Cardiac arrhythmia – irregular heart rhythm that may require monitoring.
• Persistent QT interval prolongation – measurable ECG change that can increase risk of torsades.

When prescribing Granissetrom Hameln, clinicians should consider several precautionary measures to ensure safe use.

• Check for known allergy to granisetron or other 5‑HT3 antagonists.
• Obtain a baseline ECG to assess QT interval before treatment.
• Use cautiously in hepatic impairment; dose may need adjustment.
• Monitor for constipation, particularly in patients with pre‑existing GI disorders.
• Avoid concurrent QT‑prolonging drugs unless clinical benefit justifies the risk.
• Consider limited pregnancy and lactation data; weigh potential risks and benefits.

Granissetrom Hameln may interact with other medications, influencing its safety or effectiveness.

Avoid

• Other 5‑HT3 antagonists administered concurrently.
• Strong CYP3A4 inducers that could reduce plasma levels (e.g., rifampin).

Use with caution

• Antipsychotics or antiarrhythmics that prolong QT interval (e.g., ondansetron, amiodarone).
• Opioid analgesics, as combined use may increase risk of constipation.
• Anticholinergic agents, which may exacerbate gastrointestinal side effects.
• Diuretics, because electrolyte disturbances can affect cardiac conduction.